Seres Therapeutics, Inc.

MCRB · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$8,204-$19,855$32,682-$15,637
Dep. & Amort.$1,044$1,059$1,076$1,085
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$2,340$2,819$3,765
Change in WC-$11,649$1,103-$11,712-$30,126
Other Non-Cash$4,607$2,064$2,045$2,031
Operating Cash Flow$2,206-$13,289$26,910-$38,882
Investing Activities
PP&E Inv.-$8-$181-$34-$90
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$8-$181-$34-$90
Financing Activities
Debt Repay.$0$0$0$127,905
Stock Issued$61$0$1,180$1,737
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0-$127,905
Financing Cash Flow$61$0$1,180$1,737
Forex Effect$0$0$0-$1
Net Chg. in Cash$2,259-$13,470$28,056-$37,236
Supplemental Information
Beg. Cash$45,379$67,517$39,461$76,697
End Cash$47,638$54,047$67,517$39,461
Free Cash Flow$2,198-$13,470$26,876-$38,972
Seres Therapeutics, Inc. (MCRB) Financial Statements & Key Stats | AlphaPilot